ZymoGenetics (NASDAQ: [[ticker:ZGEN]]), the Seattle-based biotech company, said today in a regulatory filing that its drug to control excess surgical bleeding has received approval from Canadian regulators. ZymoGenetics’ partner, Bayer AG, received clearance to start marketing recombinant thrombin (Recothrom), in Canada. ZymoGenetics, which first received approval of the drug in the U.S. in January 2008, will receive a $3.5 million payment in connection with the milestone.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
